ArticlePloS one2016
Engineered Production of Short Chain Fatty Acid in Escherichia coli Using Fatty Acid Synthesis Pathway.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- From dysbacteriosis to ecological remodeling: A new breakthrough in microbial treatment of inflammatory bowel disease.iScience · 2026Review
- Postbiotics: Definitions, Manufacturing, Analytical Characterization, and Clinical Evidence for Human and Animal Health.Current microbiology · 2026Review
- Glycyrrhiza, a commonly used medicinal herb: Review of species classification, pharmacology, active ingredient biosynthesis, and synthetic biology.Journal of advanced research · 2025Review
- Genomic Insights into the Probiotic Functionality and Safety ofFoods (Basel, Switzerland) · 2025Article
- Microbial Bio-refineries: Engineering Microbes for the Production of Versatile Short-Chain Organic Acids.Indian journal of microbiology · 2025Review
- How Close Are We to the Production of Milk in Alternative Systems? The Fat Perspective.Foods (Basel, Switzerland) · 2025Review
- Unravelling and reconstructing the biosynthetic pathway of bergenin.Nature communications · 2024Article
- Research on the Resource Recovery of Medium-Chain Fatty Acids from Municipal Sludge: Current State and Future Prospects.Microorganisms · 2024Review
- A strategy to enhance and modify fatty acid synthesis in Corynebacterium glutamicum and Escherichia coli: overexpression of acyl-CoA thioesterases.Microbial cell factories · 2023Article
- Metabolic adaptation to consume butyrate under prolonged resource exhaustion.PLoS genetics · 2023Article
- Article
- Kinetically guided, ratiometric tuning of fatty acid biosynthesis.Metabolic engineering · 2022Review
- Dynamic control over feedback regulatory mechanisms improves NADPH flux and xylitol biosynthesis in engineered E. coli.Metabolic engineering · 2021Article
- Recent advances in n-butanol and butyrate production using engineered Clostridium tyrobutyricum.World journal of microbiology & biotechnology · 2020Review
- High-level soluble expression of human Cu,Zn superoxide dismutase with high activity in Escherichia coli.World journal of microbiology & biotechnology · 2020Article
- Production and Sensing of Butyrate in a ProbioticInternational journal of molecular sciences · 2020Article
- Biosynthesis of Fatty Alcohols in Engineered Microbial Cell Factories: Advances and Limitations.Frontiers in bioengineering and biotechnology · 2020Review
- A Review of the Biotechnological Production of Methacrylic Acid.Frontiers in bioengineering and biotechnology · 2020Review
- CRISPR/Cas9-mediated engineering of Escherichia coli for n-butanol production from xylose in defined medium.Journal of industrial microbiology & biotechnology · 2019Article
- Biosynthesis of Medium-Chain ω-Hydroxy Fatty Acids by AlkBGT ofFrontiers in bioengineering and biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short-chain fatty acids (SCFAs), such as butyric acid, have a broad range of applications in chemical and fuel industries. Worldwide demand of sustainable fuels and chemicals has encouraged researchers for microbial synthesis of SCFAs. In this study we compared three thioesterases, i.e., TesAT from Anaerococcus tetradius, TesBF from Bryantella formatexigens and TesBT from Bacteroides thetaiotaomicron, for production of SCFAs in Escherichia coli utilizing native fatty acid synthesis (FASII) pathway and modulated the genetic and bioprocess parameters to improve its yield and productivity. E. coli strain expressing tesBT gene yielded maximum butyric acid titer at 1.46 g L-1, followed by tesBF at 0.85 g L-1 and tesAT at 0.12 g L-1. The titer of butyric acid varied significantly depending upon the plasmid copy number and strain genotype. The modulation of genetic factors that are known to influence long chain fatty acid production, such as deletion of the fadD and fadE that initiates the fatty acid degradation cycle and overexpression of fadR that is a global transcriptional activator of fatty acid biosynthesis and repressor of degradation cycle, did not improve the butyric acid titer significantly. Use of chemical inhibitor cerulenin, which restricts the fatty acid elongation cycle, increased the butyric acid titer by 1.7-fold in case of TesBF, while it had adverse impact in case of TesBT. In vitro enzyme assay indicated that cerulenin also inhibited short chain specific thioesterase, though inhibitory concentration varied according to the type of thioesterase used. Further process optimization followed by fed-batch cultivation under phosphorous limited condition led to production of 14.3 g L-1 butyric acid and 17.5 g L-1 total free fatty acid at 28% of theoretical yield. This study expands our understanding of SCFAs production in E. coli through FASII pathway and highlights role of genetic and process optimization to enhance the desired product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.